Trading Signals: BIIB Stock Price Prediction and Forecast (Fri. Mar. 14, 2014 - Fri. Dec. 22, 2023)(Biogen Inc)
| BIIB latest price $288.2699 (-4.5%) ($286.3000 - $305.4790) on Fri. Apr. 4, 2014. | |
| | Trend Analysis and Forecast | | | | Average Daily Percentage Swing | 3.2% (three month average) | | RSI | 24 | | Latest Price | $288.2699(-4.5%) | | Stocks Behave Similarly | Similar Stock List | | Daily Trend | BIIB declines -0.4% a day on average for past five trading days. | | Market Behavior | Normal for large cap. Normal for small cap. | | Correlated ETFs | Broad market will support BIIB advance at 0% a week (0% probability)
XLV(38%) XBI(34%) SPY(29%) QQQ(28%) VT(27%) | | Factors Impacting BIIB price | BIIB will decline at least -1.6% in a week (0% probabilities).
UUP(-10%) TLT(-9%) TIP(-5%) GLD(-4%) UNG(-1%) | | | | | | | | Relative Volatility | (options are extremely cheap) | | | | | Market Trend Strength | -1.6% (StdDev 3.2%) | | Hourly BBV | 0 () | | Intraday Trend | -5.1% | | | | | |
|
| 5 Day Moving Average | $303.1(-4.89%) | | 10 Day Moving Average | $304.68(-5.39%) | | 20 Day Moving Average | $0(0%) | | To recent high | -18.1% | | To recent low | 0% | | Market Cap | $45.633b | | | | | | |
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. It offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA, and FAMPYRA for the treatment of multiple sclerosis; SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA. |